5-[p-(Substituted)phenyl]-2,2-dialkyl-4-phenyl-3-oxazoline
AssigneeHoffmann-La Roche Inc.
InventorsKarl Bernauer, Karlheinz Pfoertner
Life of this patent
Estimating the term…
Abstract
Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1, prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.
Claims1
A method of treating diabetes which comprises administering to a host requiring such treatment an antidiabetically effective amount of a compound of the formula ##STR11## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl of 1 to 3 carbon atoms;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.7, independently, are hydrogen or lower alkyl of 1 to 3 carbon atoms;
- R.sup.8 is hydrogen, lower alkyl of 1 to 3 carbon atoms or formyl;
- R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl;
- and n is 0 or, when both R.sup.7 and R.sup.8 are lower alkyl of 1 to 3 carbon atoms, n is 0 or 1.
Dependencies are inferred from the claim text.